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Abstract
Background: ODM-201 is a novel second-generation androgen receptor inhibitor for the
treatment of metastatic castration-resistant prostate cancer (mCRPC).
Objective: To evaluate the pharmacokinetics of ODM-201 tablet products and preliminary
long-term safety, tolerability, and antitumor activity of ODM-201 in chemotherapy-naivemen
with mCRPC.
Design, setting, and participants: Thirty patients were enrolled in this open-label phase
1 trial. Patients received a single 600-mg dose of ODM-201 in capsules with food and one
600-mg dose of ODM-201 tablet product (TabA or TabB) with food and in the fasted state in a
random order. In the extension, patients received 600 mg twice daily ODM-201 taken with
food in capsules.
Outcomemeasurements and statistical analysis: We analyzed the pharmacokinetics of ODM-
201 tablet formulations. Safety and tolerability were assessed until disease progression or an
intolerable adverse event (AE). Antitumor activity was assessed by prostate-speciﬁc antigen
(PSA) levels and imaging.
Results and limitations: The capsule:TabA ratio of area under the concentration-time curve
from time zero to the last sample at 48 h was 1.06 (90% conﬁdence interval [CI], 0.91–1.24);
the capsule:TabB ratio was 0.97 (90% CI, 0.82–1.14). At week 12, 25 of 30 patients (83%) had a
PSA response (50% reduction from baseline). Median time to radiographic progression was
66 wk (95% CI, 41–79). Most common AEs were fatigue (n = 4 [13%]) and nausea (n = 4 [13%]).
Conclusions: The study showed that the tablet formulation of ODM-201 had similar phar-
macokinetics compared with the capsule. Treatment with a 600-mg twice daily dose of ODM-
201 provided anticancer activity and was well tolerated in men with chemotherapy-naive
mCRPC.
Patient summary: The ﬁndings of this study showed that ODM-201 is well tolerated and
provided antitumor activity in chemotherapy-naive patients with metastatic castration-
resistant prostate cancer (mCRPC) and that the 300-mg tablet formulation can be used in
further clinical studies. A phase 3 trial with ODM-201 600 mg twice daily in patientswith non-
mCRPC is ongoing.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The initial treatment for metastatic prostate cancer (PCa) is
androgen deprivation therapy, using either surgical or
chemical castration [1,2]. Although this approach usually
results in anticancer efficacy [3], most men develop
castration-resistant prostate cancer (CRPC) within 2–3 yr.
Until recently, chemotherapy with docetaxel was the only
proven treatment option for metastatic CRPC (mCRPC);
however,with increasedunderstanding of themechanisms
underlying castration resistance, two new hormonal
treatments—abiraterone [4] and enzalutamide [5]—were
recently licensed in the European Union and United States
for pre- and postdocetaxel treatment of mCRPC. Abirater-
one is an irreversible inhibitor of the CYP17A enzyme
that catalyzes the production of androgens [6]; enzaluta-
mide is a second-generation androgen receptor (AR)
antagonist.
Enzalutamide is generally well tolerated but can lead to
fatigue [5,7] and an increased risk of seizures. Although the
incidence of seizures in enzalutamide trials was low [5,7,8],
the risk of seizures in patients with predisposing factors or a
history of seizures is not known because such patients were
excluded from the trials [9].
ODM-201 is a novel oral second-generation AR inhibitor
with a similar mechanism of action to enzalutamide, but
structurally distinct, with negligible penetration of the
blood–brain barrier in preclinical studies [10]. ODM-201 is a
mixture (1:1) of two pharmacologically active diastereo-
mers: ORM-16497 and ORM-16555, which like the major
metabolite ORM-15341, have a higher affinity for the AR
than enzalutamide [10]. In preclinical studies, ODM-201
significantly inhibited tumor growth in amurine VCap CRPC
xenograft model [10]. A phase 1/2 study of ODM-201
(ARADES) in men with mCRPC was published in 2014 and
included patients with a history or at risk of seizures [11]. In
the dose-escalation part (n = 24), doses of 100–900 mg
twice daily resulted in no dose-limiting toxicity. In the
phase 2 part (n = 110), which evaluated doses of 100, 200,
and 700 mg twice daily, most patients experienced
prostate-specific antigen (PSA) decline. The best PSA
response was observed in patients treated with 700 mg
twice daily (86%) who had not previously received
chemotherapy or CYP17 inhibitors. ODM-201 was well
tolerated; >99% of adverse events (AEs) were grade 1–2
[11].
Dosing of ODM-201 in the ARADES studywas via 100-mg
capsules, necessitating the administration of a large number
of capsules in patients on higher doses. Subsequently, two
new tablet products were developed, each containing
300 mg ODM-201.
The aims of the current study (ARAFOR) were, in the first
component, to evaluate the pharmacokinetics of two tablet
products relative to the capsule formulation and to evaluate
the effect of food on ODM-201 absorption and, in the second
component, to preliminarily assess the long-term safety,
tolerability, and antitumor activity of an ODM-201 600 mg
twice-daily dose in chemotherapy-naive patients with
mCRPC (NCT01784757).
2. Methods
2.1. Trial design
This was a two-part multicenter international phase 1 study (Fig. 1A
and 1B). The ﬁrst pharmacokinetic (PK) component was a randomized
open-label, two-arm, three-period crossover study. The second part was
an open-label extension to assess long-term safety and tolerability. The
primary end point in the ﬁrst component was PK of tablet products
compared with capsule formulation and effect of food. The end points in
the second component (the extension) were safety and effects on PSA
and lesions.
2.2. Patients
Patients aged 18 yr were eligible if they had progressive mCRPC,
testosterone level <1.7 nmol/l, an Eastern Cooperative Oncology Group
performance status of 0–1, and if they had not received chemotherapy
and were asymptomatic or mildly symptomatic. Patients without
bilateral orchiectomy had to continue gonadotropin-releasing hormone
therapy during the study. Progressive disease was deﬁned as rising PSA
(two consecutive increases in PSA levels obtained at least 1 wk apart
with the lowest value2 ng/ml), radiographic disease progression based
onmodiﬁed Response Evaluation Criteria in Solid Tumors (RECIST v.1.1),
or two or more new bone lesions. Brain metastases or previous
treatment with a second-generation AR antagonist or CYP17 inhibitor
were exclusionary.
2.3. Ethics
All patients gave written informed consent for participation. The study
was approved by an independent ethics committee at each participating
center, and the study was conducted according to the principles of the
Declaration of Helsinki, Good Clinical Practice, and applicable regulatory
requirements.
2.4. Treatment
During the PK component, patients received a single oral 600-mg
dose of the reference ODM-201 capsules (6  100-mg capsules) with
food and a 600-mg dose of either of the two test tablets (TabA or
TabB, 2  300 mg) in the fed and fasted state. Patients were randomly
assigned at a 1:1 ratio to receive TabA or TabB via a electronic data
capture system and concealed through a password-protected
computer database, and to one of the three treatment sequences
according to the trial design. Arm information was blinded. TabA and
TabB were conventional immediate-release tablets. TabB was the
same formulation as TabA but with a coarser grade of the drug
substance. Dosing with food was done 30 min after a standard high-
fat high-calorie meal. There was a 7-d washout period between each
treatment period.
During the extension, patients were treatedwith a ODM-201 600-mg
capsule taken with food twice daily. Treatment continued until disease
progression or an intolerable AE.
2.5. Pharmacokinetic assessments
Blood samples were taken predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12,
24, 30, and 48 h postdose in each treatment period. Based on PK of ODM-
201 in humans [11], a washout period of 7 d was deemed appropriate to
ensure complete clearance of ODM-201 between administrations.
Plasma concentrations of ORM-16497 and ORM-16555 (diastereomers
of ODM-201) and the major metabolite ORM-15341 were determined
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using liquid chromatography with tandem mass spectrometry. The
ODM-201 concentration was the sum of the concentrations of the two
diastereomers.
The following PK parameters were calculated using Phoenix
WinNonlin software (Certara, Princeton, NJ, USA) (noncompartmental
method): maximum (peak) plasma concentration (Cmax), time to reach
maximum plasma concentration (Tmax), area under the concentration-
time curve from time zero to the last sample at 48 h (AUC0–48), area
under the concentration-time curve from time zero to inﬁnity (AUC1),
and terminal elimination half-life (t1/2). The primary parameters were
Cmax, Tmax, and AUCt. PK parameters were calculated for TabA and TabB
after administrations at fed and fasted state, and separately for capsule
in arms A and B.
2.6. Antitumor activity assessments
Disease progression was assessed by changes in PSA and soft tissue and
bone. A minimum treatment period of 12 wk was required before PSA
progression could be declared.
Computed tomography or magnetic resonance imaging of the chest,
abdomen, and pelvis were performed at baseline and every 3 mo to
assess soft tissue lesions; response was evaluated using RECIST v.1.1
criteria, with the exception of lymph node lesions, which had to be
2 cm in diameter. Radionuclide bone scans were performed at baseline
and every 3 mo. Progression in bone was assessed by Prostate Cancer
Working Group (PCWG2) criteria [12]. PSA was analyzed centrally every
4 wk until 9 mo and every 3 mo thereafter. Time to PSA progression was
[(Fig._1)TD$FIG]
Fig. 1 – Study overview: (A) trial design; (B) schedule of events.
b.i.d. = twice daily; EOS = end of study; PK = pharmacokinetic; TabA = tablet A; TabB = tablet B.
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deﬁned according to PCWG2, that is, 25% increase in PSA and an
absolute increase2 ng/ml fromnadir as conﬁrmed by an additional PSA
performed 3 wk later. Baseline PSA was deﬁned as PSA value obtained
before the ﬁrst dosing in the PK component.
2.7. Safety and tolerability
AEs were graded by the National Cancer Institute of Common
Terminology Criteria for Adverse Events (v.4.03). Laboratory assess-
ments (hematology, serum chemistry, and urinalysis) were conducted at
baseline, every 4 wk until 9 mo, and every 3 mo thereafter.
2.8. Statistical analysis
The safety population was deﬁned as all patients who took at least one
dose of ODM-201, and the PK population as all patients who received
treatment and had no major protocol violations that would compromise
reliable determination of PK parameters. The safety and intention-to-
treat (ITT) populations were the same. Efﬁcacy is reported for the ITT
population. Analyses were performed using data obtained up to the cut-
off date of October 31, 2014.
Log-transformed PK parameters (Cmax, Tmax, and AUCt) were
analyzed using analysis of variance with treatment (test product and
fed/fasted state), sequence, and period as ﬁxed effects and patient nested
in sequence as a random effect. The PK of TabA and TabB relative to the
capsule were evaluated according to the ratio of the geometric means
(and two-sided 90% conﬁdence interval [CI]) of the AUC. The effect of
food on the PK of ODM-201 in the TabA and TabB formulations was also
evaluated according to the geometric means and two-sided 90% CI. The
Wilcoxon signed rank test was used to analyze the Tmax and testosterone
data and descriptive statistics for the t1/2 data.
The planned sample size for the PK component was 30 patients
(15 in the TabA arm and 15 in the TabB arm). The sample size was
based on interpatient coefﬁcient of variation of 30% and an
intrapatient correlation coefﬁcient of 0.35, allowing the 90% CIs to
be within 0.8 R and 1.25 R, where R was the point estimate of ratios of
AUC or Cmax.
All measurements in the extension were summarized using
descriptive statistics. Time to PSA progression and radiographic
progression and time on treatment to discontinuation were deﬁned
using Kaplan-Meier estimates.
3. Results
From March 2013 to July 2013, 30 patients with CRPC in
Finland, France, and Latvia were enrolled. All patients
completed the PK component and entered the extension. By
October 31, 2014, there were 10 ongoing patients in the
study. The median reporting period for AEs was 15.3 mo
(95% CI, 9.7, not reported [NR]).
The safety and ITT populations were the same compris-
ing 30 patients. The PK population comprised 28 patients in
periods 1 and 2, and 29 patients in period 3.
3.1. Baseline characteristics
Table 1 summarizes the baseline characteristics.
3.2. Pharmacokinetics component
The tablet and capsule formulations provided similar
plasma ODM-201 concentrations over time following single
dosing (Fig. 2). The capsule:TabA ratio of AUC0–48 was
1.06 (90% CI, 0.91–1.24); the capsule:TabB ratio was 0.97
(90% CI, 0.82–1.14). The ratios of Cmax were 1.16 (90% CI,
0.99–1.36) and 1.00 (90% CI, 0.86–1.15) for TabA and TabB,
respectively. Absorption was slower and plasma exposure
Table 1 – Baseline characteristics
Total
(n = 30)
Age, yr
Median 68
Q1–Q3 65–71
Race, n (%)
White [1_TD$DIFF]30 (100)
BMI, kg/m2
Median 28.5
Q1–Q3 27.0–30.9
PSA, mg/l
Median 18.2
Q1–Q3 8.2–53.5
Time from initial diagnosis to ﬁrst dose, mo
Median 39
Q1–Q3 22–80
Initial treatment of primary tumor, n (%)
Chemical castration 16 (53)
First-generation antiandrogen 1 (3)
Prostatectomy 4 (13)
Radiotherapy 9 (30)
Prior therapy, n (%)
LHRH agonist or antagonist 30 (100)
Radiotherapy 17 (57)
First-generation antiandrogen 22 (73)
Systemic corticosteroids 1 (3)
Bone agents 1 (3)
Estrogens 1 (3)
ECOG status, n (%)
0 20 (67)
1 10 (33)
Disease localization at screening, n (%)
Bone only 14 (47)
Soft tissue only 3 (10)
Bone and soft tissue 13 (43)
Visceral 3 (10)
BMI = body mass index; ECOG = Eastern Cooperative Oncology Group;
LHRH = luteinizing hormone-releasing hormone; PSA = prostate-speciﬁc
antigen; Q1 = 25th quartile; Q3 = 75th quartile.
[(Fig._2)TD$FIG]
Fig. 2 – Plasma concentration-time curve for ODM-201 following single-
dose administration of capsule, tablet A, and tablet B.
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was about twofold greaterwhen dosingwith food compared
with the fasting state (Supplementary Table 1). Median
Tmax was 5–6 h in the fed state and about 4 h in the fasting
state. Cmax, AUCt, and AUC1 were approximately twofold
greater in the fed state compared with the fasting state.
Median Tmax for ODM-201 and the metabolite, ORM-
15341, were similar. Meanmetabolite-to-parent ratios were
similar for the capsule and tablets and were not affected by
food (Cmax: 1.5–1.8; AUC: 1.4–1.7). Similar to the effect on
ODM-201, food increased the Cmax, AUCt, and AUC1 of ORM-
15341 approximately twofold compared with the fasted
state. Food had no effect on the diastereomer ratio.
3.3. Extension component: antitumor activity and safety
All 30 patients completed the first 12wk in the extension. At
12 wk the PSA response rate (PSA decrease from baseline
50%) was 83% (25 of 30); of these patients, 30% (9 of 30)
had a PSA reduction90% (Fig. 3A). The median time to PSA
progression was 54 wk (95% CI, 23–NR) (Fig. 3B). Table 2
summarizes the soft tissue responses and bone results at
12 wk. The median time to radiographic progression was
66 wk (95% CI, 41–79) (Fig. 3C).
Median serum testosterone level at 12 wk was lower
than at baseline (0.60 nmol/l and 0.80 nmol/l, respectively;
p = 0.5).
A total of 22 of 30 patients (73%) reported AEs;mostwere
grade 1–2 (114 of 125 [91%]). The most common AEs were
fatigue (all grade 1) in four patients (13%) and nausea (grade
1–3) in four patients (13%) (Table 3). Events in six patients
(20%) were considered by the investigator to be related to
ODM-201: fatigue, decreased appetite, headache, abdomi-
nal pain, solar dermatitis, tinnitus, and dysgeusia. All
treatment-related AEs were grade 1. No dose reductions
were made. One patient (3.3%) died because of progression
of PCa, and two patients (6.7%) discontinued due to an AE
(neuroendocrine carcinoma and respiratory failure). None
of the events were considered by the investigator to be
related to ODM-201. No seizures were reported.
4. Discussion
Results of this study showed that ODM-201 was well
tolerated and demonstrated anticancer activity inmenwith
mCRPC.
[(Fig._3)TD$FIG]
Fig. 3 – (A) Percentage change in prostate-specific antigen (PSA) at 12 wk compared with baseline, (B) time to PSA progression by Prostate Cancer
Working Group 2 criterion, and (C) time to radiographic progression.
PSA = prostate-specific antigen.
Table 2 – Soft tissue and bone imaging results at 12 wk
Response Category n (%)
No. of patients with soft tissue evaluable – 21 (100)
RECIST response CR 2 (10)
PR 4 (19)
SD 13 (62)
PD 2 (10)
No. of patients evaluable for bone scan – 27 (100)
Bone SD 21 (78)
PD 6 (22)
CR = complete response; PD = progressive disease; PR = partial response;
RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease.
E U RO P E AN URO LOGY 6 9 ( 2 0 1 6 ) 8 3 4 – 8 4 0838
In the fed state, the pharmacokinetics of 600 mg ODM-
201 in the two tablet and capsule formulations was similar
and absorption was approximately twofold greater com-
pared with the fasted state. These data suggest the tablet
formulation taken with food would be suitable for further
investigation in phase 3 studies and can reduce the dosing
burden on patients.
Antitumor activity was shown by significant PSA
reductions. The soft tissue and bone lesion data, as well
as time to PSA progression and radiographic progression,
provided evidence of antitumor activity of ODM-201. The
PSA response (50% decrease) at 12 wk was 83%, similar to
the PSA response of 86% in the ARADES study [11] observed
in chemotherapy-naive patients at 700 mg twice daily. The
median time to PSA progression was 55 wk; the median
time to radiographic progression was 66 wk.
No statistically significant changes (p = 0.5) were ob-
served in median serum testosterone level between
baseline and week 12, suggesting negligible brain penetra-
tion of ODM-201 and lack of effect on the hypothalamic-
pituitary-gonadal axis.
ODM-201 was well tolerated in this study. Similar to the
ARADES study [11], most AEs were grade 1–2, all treatment-
emergent AEs were grade 1, and no dose reductions were
required for any patient. The frequency of AEs commonly
reported in patients treated with second-generation [2_TD$DIFF]AR
inhibitors was low, similar to or lower than the AE rate
reportedbypatients in the placebo armof a phase3 trialwith
a comparable population of patients with chemotherapy-
naive mCRPC [7].
Preclinical studies inmice and rats have shown negligible
penetrance of ODM-201 through the blood–brain barrier
[10], and therefore it is not expected to increase the risk of
seizures. In contrast, other recently developed second-
generation AR inhibitors, enzalutamide and AR-509, were
shown to cross the blood–brain barrier in preclinical in vivo
models, potentially increasing the risk of seizures by
inhibiting g-aminobutyric acid–gated chloride channels in
the brain [13,14]. Patients with a history of seizures or
any predisposing conditions were excluded from the phase
1/2 and 3 trials with enzalutamide [5,7,8] and ARN-509
[15,16], but they were allowed to enter the ARADES study
[11] and the current study, where no seizureswere reported.
The differences in brain penetration between ODM-201
and the other second-generation AR inhibitors is likely
related to the unique structure of ODM-201.
5. Conclusions
The current study demonstrated that the 600-mg ODM-201
tablet formulation has similar PK to the capsule formulation
and that ODM-201 treatment is well tolerated and exhibits
antitumor activity inmenwith CRPC. Based on the results of
this study, ODM-201 600 mg is given to patients twice daily
as tablets in the randomized placebo-controlled phase
3 study ARAMIS, in men with high-risk non-mCRPC to
evaluate the effect of ODM-201 on metastasis-free survival.
Interim data presented at the Genitourinary Cancers
Symposium, January 30–February 1, 2014, San Francisco,
California, and February 26–28, 2015, Orlando, Florida, and
at the 29th European Association of Urology Congress, April
11–15, 2014, Stockholm, Sweden.
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